Analyst recommendations: Boohoo, Boston Beer, Cisco Systems, Eversource, Frontline...
Every day, find a selection of analysts' recommendations covering North America and the U.K. The list only includes companies that have been the subject of a change of opinion or price target, or a new coverage. It may be updated during the session. This information can be used to shed light on the movements of certain shares or the market sentiment on a company.
- Atlassian : Baird adjusts price target to $400 from $345, keeps outperform rating
- Belden: Canaccord Genuity raised the recommendation to buy from hold. PT up 19% to $68
- BioMarin: Stifel upgrades to buy from hold. PT raised 25% to $96
- Boohoo: Credit Suisse upgrades from neutral to outperform with a GBP 350 target.
- The Boston Beer Company : UBS lowers pt to $850 from $1,080, maintains buy rating
- Cimarex Energy : Truist Securities adjusts pt to $100 from $80, maintains buy rating
- Cisco Systems: Morgan Stanley downgrades to equal-weight from overweight. PT adjusted by 0.5% to $59
- Diamondback Energy : Barclays adjusts price target to $100 from $95, keeps equalweight rating
- Draper: Jefferies upgrades from buy to hold with a target of GBp 1,200.
- Eversource: Mizuho Securities cut the recommendation to underperform from neutral. PT down 7.5% to $85
- Frontline: Pareto Securities raised the recommendation to buy from hold. PT up 32% to $10.22
- Goodrich Petroleum : Wells Fargo downgrades to hold from buy, adjusts price target to $23 from $21
- Grainger: Peel Hunt upgrades to buy targeting GBP 370.
- Hunting: Jefferies remains Buy with a reduced target price of GBP 350 to GBP 300.
- Ocwen: B Riley Securities initiated coverage of Ocwen Financial Corp. with a recommendation of buy. PT set to $50, implies a 84% increase from last price. Ocwen average PT is $39.33
- Pure Storage : Northland Securities upgrades pure storage to outperform from market perform, lifts pt to $36 from $26
- Spire Global : Baird initiates coverage on spire global with neutral rating, $12 price target
- Surmodics : Needham & Co adjusts pt to $76 from $68, maintains buy rating
- Vertex Pharmaceuticals: Stifel downgrades to hold from buy. PT up 11% to $213
© MarketScreener.com 2021